PTPRC and neoplasm: Importantly, there were multiple ligand-receptor interactions within the same tumor-CD8 pairs, and among the recognized G9 interacting partners, PTPRC (CD45) that bears glycan chains, was likely to be the major counterpart (Fig. 1L).